JPMorgan Pushes Past $357 as Short Sellers Quietly Retreat

The Street story has evolved materially since the Q2 beat. Last week's report noted the consensus mean at $371.25. That figure holds at $371.85 today, with the stock now at $357.31 — implying roughly 4% upside to consensus versus the 7% gap that existed just two weeks ago. The compression has been rapid. The analyst cluster that moved targets post-earnings — BofA at $420, Barclays at $420, Wells Fargo at $375, RBC at $370 — reflects genuine conviction in JPMorgan's earnings power. The cautious end of the range remains anchored by Baird at $305, a Neutral that looks increasingly lonely as the stock trades through most of the field's targets. The factor data backs the bull side: JPMorgan ranks in the 95th percentile on 30-day EPS momentum and the 94th percentile on EPS surprise — two measures that have repeatedly reflected the bank's tendency to outdeliver on estimates. The P/E is running at 14.6x and price-to-book at 2.5x, both modestly higher over the past month as the stock has re-rated upward. Forward EPS estimates for 2026 show year-on-year growth of 291%, per the ORTEX factor model, though that figure likely reflects base effects from a low prior-year comparison rather than organic acceleration of that magnitude.

Among peers, JPMorgan has been the week's clear outperformer. It gained 3.5% over the seven sessions ending July 28. Bank of America added 2.3% over the same period. U.S. Bancorp put on 1.1%. Wells Fargo and Citigroup both shed around half a percent on the week. KeyCorp fell 1.4% and Huntington Bancshares dropped nearly 5%. That divergence reinforces JPMorgan's current status as the group's momentum anchor — a stock that has been bid through the sector's noise rather than moved with it.

Insider activity over the past 90 days has been uniformly in one direction: senior executives selling. The General Counsel, multiple divisional CEOs, the COO, CFO, and Chief Risk Officer have all sold shares in the May-to-June window, with transactions ranging from roughly $950,000 to $3.8 million. The net 90-day figure shows 343,890 shares sold at a total value just above $104 million. These are predominantly scheduled program sales — trade significance scores are all at the low end of the scale — but the breadth of sellers across the C-suite is worth noting as the stock trades at all-time highs. No offsetting buys from executives are visible in the recent window.

With Q3 earnings not until October 13, the near-term question for JPMorgan is whether the stock can hold above $357 — now above the mean analyst target as recently as two weeks ago — and whether the short interest rebuild that began on July 22 represents a new tactical ceiling or simply a timing artefact around the post-earnings re-rating.